Table 3.

Sensitivity analyses of selected variables with ICERs calculated to compare strategies

VariablesStrategy
Primary vs noneSecondary vs nonePrimary vs secondary
Survival for early gastric cancer per year, %
    6217.0K*Dominant
    7017.0K258.8KDominant
    8017.0K120.2KDominant
    9017.0K58.0KDominant
    97.9, base17.0K29.7KDominant
Acquisition and reinfection of H. pylori per year, %
    0.510.3K30.5KDominant
    1, base17.0K29.7KDominant
    1.522.5K29.0K12.6K
    2.2, threshold29.6K28.3K28.3K
    2.530.3K28.0K33.6K
Attendance rate for prevention program, %
    205.5K31.5KDominant
    4010.9K31.3KDominant
    60, base16.0K31.4KDominant
    8020.9K31.3KDominant
    10025.6K31.3KDominant
Sensitivity of pepsinogen method for gastritis stages to AG, %
    5017.0K31.7KDominant
    6017.0K29.9KDominant
    70.5, base17.0K29.7KDominant
    8017.0K28.3KDominant
    9017.0K27.4KDominant
Attendance for endoscopy, %
    3017.0K49.6K6.3K
    4017.0K41.2K5.1K
    5017.0K36.3K3.6K
    6017.0K32.9K1.6K
    74, base17.0K29.7KDominant
Proportion of early gastric cancer detected on endoscopy, %
    1017.0K97.7KDominant
    30, base17.0K29.7KDominant
    50, threshold17.0K17.0K20.3K
    7017.0K11.7K*
    9017.0K8.7K*
Costs of endoscopy with biopsy, U.S. $
    11, threshold17.0K16.9K17.3K
    68.8, base17.0K29.7KDominant
    10017.0K41.9KDominant
    40017.0K119.3KDominant
    80017.0K139.8KDominant
Discount rate, %
    110.5K25.8KDominant
    213.5K27.5KDominant
    3, base17.0K29.7KDominant
    420.9K32.3K8.7K
    524.9K35.5K17.0K
  • NOTE: K = ×1,000.

  • * Reference strategy was dominant.

  • Dominant = more effective and less costly than reference strategy.

  • Threshold = the value of variable giving a similar ICER among strategies.